Sage Therapeutics (NASDAQ:SAGE) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sage ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in ...

BofA withdrew its rating on SAGE in January after the depression drug developer said that Biogen (NASDAQ:BIIB) agreed to buy ...

“With the commercial momentum behind ZURZUVAE, a focused approach to R&D, and an extended cash runway to mid-2027, we believe Sage is well positioned for commercial growth and value creation.

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have lost about 11.1% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Across the recent three months, 14 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), expressing a variety of opinions spanning from bullish to bearish. In the table below ...

Ratings for Sage Therapeutics (NASDAQ:SAGE) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary ...

In the last three months, 20 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...

SAGE-217 secured the regulatory nod in August ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

In the last three months, 4 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise ...

A class action lawsuit was filed against Sage Therapeutics (SAGE) by Levi & Korsinsky on August 28, 2024. The plaintiffs (shareholders) alleged that they bought SAGE stock at artificially inflated ...

Across the recent three months, 19 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), expressing a variety of opinions spanning from bullish to bearish. The following table ...